<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>2(Suppl 3)</volume><submitter>Slingluff C</submitter><journal>Journal for immunotherapy of cancer</journal><pagination>P60-P60</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4288705</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>A randomized pilot trial evaluating safety and immunogenicity of recMAGE-A3 + AS15 immunotherapeutic administered by intramuscular versus intradermal/subcutaneous routes</pubmed_title><pmcid>PMC4288705</pmcid><pubmed_authors>Chianese-bullock K</pubmed_authors><pubmed_authors>Smolkin M</pubmed_authors><pubmed_authors>Hornillo A</pubmed_authors><pubmed_authors>Grosh W</pubmed_authors><pubmed_authors>Slingluff C</pubmed_authors><pubmed_authors>Weiss G</pubmed_authors><pubmed_authors>Galeassi N</pubmed_authors><pubmed_authors>Petroni G</pubmed_authors><pubmed_authors>Olson W</pubmed_authors><pubmed_authors>Smith K</pubmed_authors><pubmed_authors>Scott K</pubmed_authors></additional><is_claimable>false</is_claimable><name>A randomized pilot trial evaluating safety and immunogenicity of recMAGE-A3 + AS15 immunotherapeutic administered by intramuscular versus intradermal/subcutaneous routes</name><description/><dates><release>2014-01-01T00:00:00Z</release><publication>2014 Jan</publication><modification>2025-04-22T07:19:32.615Z</modification><creation>2025-04-05T22:02:57.492Z</creation></dates><accession>S-EPMC4288705</accession><cross_references/></HashMap>